Brief: Hutchmed (China) Says Frusica-2 Phase II/III Study Met Primary Endpoint

HUTCHMED (China)

19/03/2025 01:18

March 19 (Reuters) - HUTCHMED (China) 0013.HK:

FRUSICA-2 PHASE II/III STUDY OF FRUQUINTINIB & SINTILIMAB COMBINATION MET PRIMARY ENDPOINT IN CHINA

Further company coverage: 0013.HK

 ((Reuters.Briefs@thomsonreuters.com;))